72996-78-2

Basic information

• Product Name: methyl 4-[(propionyl)phenylamino]piperidine-4-carboxylate
• Synonyms: methyl 4-[(propionyl)phenylamino]piperidine-4-carboxylate;Methyl 4-(N-phenylpropionamido)piperidine-4-carboxylate;4-(N-phenylpropionamido)piperidine-4-carboxylate;4-[(1-Oxopropyl)phenylamino]-4-piperidinecarboxylic acid methyl ester;4-[Propanoyl(phenyl)amino]piperidine-4-carboxylic acid methyl ester;G-194219;Methyl-4-(phenyl(propionyl)amino)piperidine-4-carboxylate;Norcarfentanil
• CAS NO: 72996-78-2
• Molecular Formula: C₁₆H₂₂N₂O₃
• Molecular Weight: 290.35748
• EINECS: 277-193-5
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 72996-78-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 40-43°C
• Boiling Point: 408.8 °C at 760 mmHg
• Flash Point: 201.1 °C
• Appearance: /
• Density: 1.151
• Vapor Pressure: 7.41E-08mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: Refrigerator
• PKA: 9.14±0.10(Predicted)
• CAS DataBase Reference: methyl 4-[(propionyl)phenylamino]piperidine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-[(propionyl)phenylamino]piperidine-4-carboxylate(72996-78-2)
• EPA Substance Registry System: methyl 4-[(propionyl)phenylamino]piperidine-4-carboxylate(72996-78-2)

Safety Data

• Hazardous Substances Data: 72996-78-2(Hazardous Substances Data)

Usage

Chemical Properties

Low Melting Brown Solid

Uses

Intermediate in the preparation of Fentanyl analogues

InChI:InChI=1/C16H22N2O3/c1-3-14(19)12-6-4-5-7-13(12)18-16(15(20)21-2)8-10-17-11-9-16/h4-7,17-18H,3,8-11H2,1-2H3

Upstream product

• 61085-72-1 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-benzyl-4-piperidinecarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 61085-60-7 methyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylate 
• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 1096-03-3 1-benzyl-4-phenylaminopiperidine-4-carboxylic acid amide 
• 85098-64-2 1-benzyl-4-(phenylamino)piperidine-4-carboxylic acid 
• 62-53-3 aniline 
• 1159835-40-1 1-tert-butyl 4-methyl 4-(N-phenylpropionamido)piperidine-1,4-dicarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1159835-31-0 1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid 
• 130819-94-2 1-benzyl-4-(propionanilido)piperidine-4-carbonitrile 
• 61085-73-2 Methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(phenylmethyl)-4-piperidinecarboxylate oxalate 

Downstream Products

• 131728-67-1 1-(1H-Benzoimidazol-2-ylmethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 131728-87-5 N-(phenyl)-N-[1-(7-methoxy-2-oxo-2H-benzopyran-4-yl(methyl))-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 131728-89-7 N-(phenyl)-N-[1-(1,4-benzodioxan-2-yl(methyl))-4-methoxycarbonyl-4-piperidinyl]propanamide 
• 69049-29-2 1-[2-(4-benzyl-5-oxo-4,5-dihydro-tetrazol-1-yl)-ethyl]-4-(N-propionyl-anilino)-piperidine-4-carboxylic acid methyl ester 
• 131728-81-9 N-(phenyl)-N-[1-(2-(5-chloro-2,3-dihydro-2-oxo-benzoxazol-3-yl)-ethyl)-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 131728-23-9 N-(phenyl)-N-[1-(2-(2,6-dioxo-3-ethyl-3-phenylpiperidin-1-yl)ethyl)-4-methoxycarbonyl-4-piperidinyl]propanamide 
• 132876-50-7 1-(2-tert-Butoxycarbonyl-ethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132876-42-7 1-[2-(2,2-Dimethyl-propoxycarbonyl)-ethyl]-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132876-28-9 1-(2-Isopropoxycarbonyl-ethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132876-26-7 4-(Phenyl-propionyl-amino)-1-(2-propoxycarbonyl-ethyl)-piperidine-4-carboxylic acid methyl ester 
• 132875-63-9 1-(3-Methoxycarbonyl-propyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132876-32-5 1-(2-Isobutoxycarbonyl-ethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132875-66-2 1-(4-Methoxycarbonyl-butyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 132876-34-7 1-(2-sec-Butoxycarbonyl-ethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 

Relevant articles and documents

FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING

This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

Alternate Process for Remifentanil Preparation

An alternate process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, a process of synthesizing synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed.

Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents

The synthesis, evaluation, and molecular modeling of a series of 18F-labeled 4-anilidopiperidines with high affinities for the μ-opioid receptor (μ-OR) are reported. On the basis of the high brain uptake and selective retention in brain regions that contain a high concentration of the μ-OR, combined with a good metabolic stability, [ 18F]fluoro-pentyl carfentanil ([18F]4) and 2-(±)[18F]-fluoropropyl-sufentanil ([18F]6) were selected as the lead compounds for further evaluation. The binding affinity to the human μ-OR was 0.74 and 0.13 nM for [18F]4 and [ 18F]6, respectively. In vitro autoradiography of [18F] 4 and [18F] 6 on rat brain sections produced patterns in accordance with the known distribution of μ-OR expression. Structure-activity relationships of the fluorinated compounds are discussed with respect to the interaction with an activated-state model of the μ-OR. Taken together, the in vivo and in vitro data indicate that [18F] 4 and [18F] 6 hold promise for studying the μ-opioid receptor in humans by means of positron emission tomography.